MENLO PARK, Calif., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced the agenda and event details for its Investor Symposium on Tuesday, September 15. The meeting will feature a panel of internationally renowned pediatric endocrinologists who will share their perspectives, experiences and insights regarding pediatric GHD. Versartis management will also update recent company activities including the status of the current somavaratan clinical programs and upcoming milestones including an update on the planned 6-month interim analyses in the VELOCITY trial.
|Growth Hormone Therapy for Childhood GHD - Current Treatment Issues in the United States||Philippe Backeljauw, MD – Professor of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center|
| Diagnosis and Treatment of GHD, A European Perspective ||Jan-Maarten Wit, MD, PhD – Emeritus Professor of Pediatrics, Department of Pediatrics, Leiden University Medical Center, The Netherlands|
|History of Growth Hormone Treatment & Treatment Approaches in Japan||Noriyuki Namba, MD, PhD – Chief of Pediatrics, Japan Community Health Care Organization (JCHO), Osaka Hospital|
| Somavaratan Pediatric GHD Development Program ||Bradley S. Miller, MD, PhD – Associate Professor, Department of Pediatric Endocrinology, University of Minnesota Masonic Children's Hospital|
|Versartis Company Update||Jay Shepard, President and Chief Executive Officer, Versartis|
The meeting will be held on Tuesday, September 15 from 8:00 a.m. to 10:00 a.m. ET at the NASDAQ MarketSite located on W. 43rd St. and Broadway in New York City. To register for this event, please send an email request to IR@versartis.com with your name, company and phone number.
An audio webcast of the Versartis Investor Symposium will be available on the investor relations section of Versartis' website at www.versartis.com. A replay of the presentation will be available for 90 days.
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone for the treatment of growth hormone deficiency (GHD). Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. The Company completed the Phase 2a stage of a Phase 1b/2a trial evaluating weekly, twice-monthly and monthly dosing regimens of somavaratan in children with GHD in June 2014 and initiated a global Phase 3 registration trial, VELOCITY, in GHD children in January 2015. In addition, the Company initiated a Phase 2/3 trial in Japan for children with GHD in April 2015 and a Phase 2 trial, VITAL, evaluating monthly dosing for adults with GHD. Additional information on Versartis clinical trials can be found at www.versartistrials.com. Further information on Versartis can be found at www.versartis.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our success being heavily dependent on somavaratan; somavaratan being a new chemical entity; the risk that somavaratan may not have favorable results in clinical trials or receive regulatory approval; potential delays in our clinical trials due to regulatory requirements or difficulty identifying qualified investigators or enrolling patients; the risk that somavaratan may cause serious side effects or have properties that delay or prevent regulatory approval or limit its commercial potential; the risk that we may encounter difficulties in manufacturing somavaratan; if somavaratan is approved, risks associated with its market acceptance, including pricing and reimbursement; potential difficulties enforcing our intellectual property rights; our reliance on our license of intellectual property from Amunix Operating, Inc. and our need for additional funds to support our operations. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2014, and in our Quarterly Report on Form 10-Q for the three months ended June 30, 2015, which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CONTACT: Corporate & Investors: Joshua Brumm Chief Financial Officer (650) 963-8582 IR@versartis.com Investors: Nick Laudico/David Burke The Ruth Group (646) 536-7030/7009 email@example.com firstname.lastname@example.org Media: Debra Bannister Corporate Communications (530) 676-7373 email@example.com